VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Thursday, January 8, 2026

Stock Comparison

Boston Scientific Corporation vs The Clorox Company

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Boston Scientific Corporation

BSX · New York Stock Exchange

Market cap (USD)$141.5B
Gross margin (TTM)65.1%
Operating margin (TTM)17.3%
Net margin (TTM)14.4%
SectorHealthcare
IndustryMedical - Devices
CountryUS
Data as of2026-01-04
Moat score
65/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Boston Scientific Corporation's moat claims, evidence, and risks.

View BSX analysis

The Clorox Company

CLX · New York Stock Exchange

Market cap (USD)$12.4B
Gross margin (TTM)44.1%
Operating margin (TTM)15%
Net margin (TTM)11.7%
SectorConsumer
IndustryHousehold & Personal Products
CountryUS
Data as of2025-12-25
Moat score
57/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into The Clorox Company's moat claims, evidence, and risks.

View CLX analysis

Comparison highlights

  • Moat score gap: Boston Scientific Corporation leads (65 / 100 vs 57 / 100 for The Clorox Company).
  • Segment focus: Boston Scientific Corporation has 5 segments (49.8% in Cardiology); The Clorox Company has 9 segments (33% in Cleaning (U.S.)).
  • Moat breadth: Boston Scientific Corporation has 6 moat types across 3 domains; The Clorox Company has 4 across 3.

Primary market context

Boston Scientific Corporation

Cardiology

Market

Cardiology devices (interventional cardiology, structural heart, electrophysiology, cardiac rhythm management and remote monitoring)

Geography

Global

Customer

Hospitals/cath labs/EP labs and specialty clinics (cardiologists, electrophysiologists)

Role

Medical device OEM / implantables + procedure devices + service-enabled monitoring

Revenue share

49.8%

The Clorox Company

Cleaning (U.S.)

Market

U.S. household cleaning & disinfecting products

Geography

United States

Customer

Consumers

Role

Brand owner / manufacturer

Revenue share

33%

Side-by-side metrics

Boston Scientific Corporation
The Clorox Company
Ticker / Exchange
BSX - New York Stock Exchange
CLX - New York Stock Exchange
Market cap (USD)
$141.5B
$12.4B
Gross margin (TTM)
65.1%
44.1%
Operating margin (TTM)
17.3%
15%
Net margin (TTM)
14.4%
11.7%
Sector
Healthcare
Consumer
Industry
Medical - Devices
Household & Personal Products
HQ country
US
US
Primary segment
Cardiology
Cleaning (U.S.)
Market structure
Oligopoly
Oligopoly
Market share
n/a
n/a
HHI estimate
n/a
n/a
Pricing power
Moderate
Moderate
Moat score
65 / 100
57 / 100
Moat domains
Demand, Legal, Supply
Demand, Supply, Legal
Last update
2026-01-04
2025-12-25

Moat coverage

Shared moat types

Installed Base ConsumablesDistribution Control

Boston Scientific Corporation strengths

Procurement InertiaTraining Org Change CostsRegulated Standards PipeReputation Reviews

The Clorox Company strengths

Brand TrustCompliance Advantage

Segment mix

Boston Scientific Corporation segments

Full profile >

Endoscopy

Oligopoly

16%

Urology

Competitive

13.1%

Neuromodulation

Oligopoly

6.6%

Cardiology

Oligopoly

49.8%

Peripheral Interventions

Competitive

14.4%

The Clorox Company segments

Full profile >

Cleaning (U.S.)

Oligopoly

33%

Professional Products (U.S.)

Oligopoly

5%

Bags and Wraps (U.S.)

Duopoly

11%

Cat Litter (U.S.)

Oligopoly

9%

Grilling (U.S.)

Oligopoly

8%

Food (U.S.)

Competitive

11%

Water Filtration (U.S.)

Oligopoly

4%

Natural Personal Care (U.S.)

Competitive

3%

International (Ex-U.S.)

Competitive

15%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.